Mammoth, GSK to take CRISPR diagnostics beyond the centralized lab

Mammoth’s new partnership with GSK builds on the momentum CRISPR-based diagnostics are generating during the COVID-19 pandemic and applies the technology where its benefits will be most apparent: the point-of-care and at-home settings.

The companies teamed up to develop a disposable, handheld test to detect SARS-CoV-2 viral RNA based on Mammoth Biosciences’ DETECTR (DNA ENdonuclease Targeted CRISPR Trans Reporter) platform, which uses Cas12a to rapidly signal the presence of specific viral RNA sequences. Financial terms of the deal were not disclosed...